Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Spyre Therapeutics Inc (SYRE)

Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,703,305
  • Shares Outstanding, K 77,592
  • Annual Sales, $ 0 K
  • Annual Income, $ -208,020 K
  • EBIT $ -214 M
  • EBITDA $ -225 M
  • 60-Month Beta 3.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.79

Options Overview Details

View History
  • Implied Volatility 90.91% (+7.57%)
  • Historical Volatility 54.20%
  • IV Percentile 21%
  • IV Rank 19.03%
  • IV High 222.63% on 09/16/25
  • IV Low 59.96% on 08/18/25
  • Expected Move (DTE 7) 4.51 (12.30%)
  • Put/Call Vol Ratio 109.33
  • Today's Volume 993
  • Volume Avg (30-Day) 86
  • Put/Call OI Ratio 1.09
  • Today's Open Interest 1,982
  • Open Int (30-Day) 2,534
  • Expected Range 32.13 to 41.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.66
  • Number of Estimates 5
  • High Estimate -0.17
  • Low Estimate -1.31
  • Prior Year -0.81
  • Growth Rate Est. (year over year) +18.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.92 +18.47%
on 02/04/26
37.93 -3.43%
on 02/13/26
+5.10 (+16.18%)
since 01/13/26
3-Month
22.13 +65.55%
on 11/14/25
37.93 -3.43%
on 02/13/26
+14.00 (+61.86%)
since 11/13/25
52-Week
10.91 +235.75%
on 04/09/25
37.93 -3.43%
on 02/13/26
+13.95 (+61.51%)
since 02/13/25

Most Recent Stories

More News
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 36.63 (+5.14%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 36.63 (+5.14%)
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

“6 in ’26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment...

SYRE : 36.63 (+5.14%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 36.63 (+5.14%)
A Short Squeeze Could Send This Little-Known Biotech Stock Soaring

Spyre Therapeutics (SYRE) has strong technical momentum and is trading at a new 52 week high. SYRE maintains a 100% “Buy” opinion from Barchart. Shares are up more than 50% in the past month. High...

SYRE : 36.63 (+5.14%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 36.63 (+5.14%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 36.63 (+5.14%)
Spyre Therapeutics: Q3 Earnings Snapshot

Spyre Therapeutics: Q3 Earnings Snapshot

SYRE : 36.63 (+5.14%)
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice...

SYRE : 36.63 (+5.14%)
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7...

SYRE : 36.63 (+5.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Spyre Therapeutics is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches for patient selection. Spyre Therapeutics, formerly known as Aeglea BioTherapeutics Inc., is based...

See More

Key Turning Points

3rd Resistance Point 36.64
2nd Resistance Point 35.78
1st Resistance Point 35.31
Last Price 36.63
1st Support Level 33.98
2nd Support Level 33.12
3rd Support Level 32.65

See More

52-Week High 37.93
Last Price 36.63
Fibonacci 61.8% 27.61
Fibonacci 50% 24.42
Fibonacci 38.2% 21.23
52-Week Low 10.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar